---
document_datetime: 2025-07-16 12:58:24
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/opuviz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: opuviz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.7708754
conversion_datetime: 2025-12-22 08:18:56.549886
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Opuviz

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc.Article61(3)-Accepted | 16/07/2025                          |                                          | PL                              |           |

1Notifications areissuedfortypeIvariations andArticle61(3)notifications(unlesspartofagroupincludinga typeIIvariationorextensionapplicationoraworksharingapplication).Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),Annex II,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annex II, labelling,package leaflet).The CDisissuedwithintwomonthsof theopinionforvariationsfallingunderthescopeofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000281956                     | Updateofthepackageleaflettodeletethe listofcontactdetailsof localrepresentatives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |             |                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation typeIB/ EMA/VR/0000265733  | C.1.2 Change(s) in the Summary ofProduct Characteristics,LabellingorPackageLeaflet of ageneric/hybrid/biosimilarmedicinal productsfollowing assessmentof thesame change for the reference product-C.I.2.a Implementation ofchange(s)forwhich no new additional data is required to be submittedbytheMAH-Accepted C.I.2.a-To update section 4.8 of the SmPC in order to add 'scleritis' to the list of adverse drug reaction (ADRs) with frequency of'0.2casesper1 milion injections'based on pharmacovigilance data, following assessmentofthesamechangeforthe reference product Eylea.ThePL is updated accordingly.Additionally,the MAH took the opportunity to update the SmPC and PL to addwarningsforpolysorbate20inlinewith theECExcipient Guideline. | 14/05/2025 | SmPC and PL | Toupdatesection4.8oftheSmPCinordertoadd 'scleritis' to the list of adverse drug reaction (ADRs), following assessment of the same change for the referenceproduct Eylea.ThePL is updated accordingly.Additionally,theMAHtookthe opportunity to update the SmPC and PL to add warningsforpolysorbate20inlinewiththeEC Excipient Guideline. |
| Variation typeII / EMA/VR/0000254853 | B.I.a.2Changes in themanufacturing process of the active substance - B.I.a.2.c Thechangereferstoabiological/ immunologicalsubstanceoruseofa differentchemicallyderivedsubstanceinthe manufactureofabiological/immunological substance,whichmayhavea significant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/05/2025 |             |                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| impact on the quality, safety and efficacy of the medicinal product and is not related to a  protocol - Accepted   |
|--------------------------------------------------------------------------------------------------------------------|